Vivo Capital LLC Makes New $17.76 Million Investment in Chiasma Inc (NASDAQ:CHMA)
Vivo Capital LLC bought a new position in Chiasma Inc (NASDAQ:CHMA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 2,377,213 shares of the biotechnology company’s stock, valued at approximately $17,758,000. Chiasma makes up approximately 1.7% of Vivo Capital LLC’s portfolio, making the stock its 19th largest holding. Vivo Capital LLC owned 0.07% of Chiasma as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Fosun International Ltd bought a new position in shares of Chiasma in the 2nd quarter worth approximately $923,000. Deutsche Bank AG raised its position in shares of Chiasma by 27.8% in the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 16,996 shares in the last quarter. Strs Ohio bought a new position in shares of Chiasma in the 2nd quarter worth approximately $560,000. Millennium Management LLC bought a new position in shares of Chiasma in the 4th quarter worth approximately $41,000. Finally, Altshuler Shaham Ltd raised its position in shares of Chiasma by 143.2% in the 2nd quarter. Altshuler Shaham Ltd now owns 101,953 shares of the biotechnology company’s stock worth $762,000 after acquiring an additional 60,026 shares in the last quarter. 53.19% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Scott Minick acquired 9,818 shares of Chiasma stock in a transaction that occurred on Tuesday, August 20th. The stock was bought at an average price of $5.19 per share, with a total value of $50,955.42. Following the transaction, the director now directly owns 62,531 shares in the company, valued at $324,535.89. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Roni Mamluk sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $6.35, for a total value of $63,500.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $63,500. The disclosure for this sale can be found here. 8.30% of the stock is owned by company insiders.
Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.04. As a group, sell-side analysts forecast that Chiasma Inc will post -1.09 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on CHMA shares. Piper Jaffray Companies started coverage on Chiasma in a research report on Wednesday, July 31st. They issued an “overweight” rating and a $11.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Chiasma in a research report on Tuesday, July 23rd. ValuEngine lowered Chiasma from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Cantor Fitzgerald set a $18.00 target price on Chiasma and gave the stock a “buy” rating in a research report on Friday, June 28th. Finally, Brookline Capital Management reissued a “buy” rating on shares of Chiasma in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Chiasma has a consensus rating of “Buy” and a consensus target price of $12.35.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Recommended Story: Buy-Side Analysts
Want to see what other hedge funds are holding CHMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chiasma Inc (NASDAQ:CHMA).
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.